Bond Thomas E H, Sorenson Alanna E, Schaeffer Patrick M
Comparative Genomics Centre, James Cook University, DB21, James Cook Drive, Townsville, QLD 4811, Australia.
Comparative Genomics Centre, James Cook University, DB21, James Cook Drive, Townsville, QLD 4811, Australia.
Microbiol Res. 2017 Jun;199:40-48. doi: 10.1016/j.micres.2017.03.007. Epub 2017 Mar 19.
Burkholderia pseudomallei (Bp) is the causative agent of melioidosis. The bacterium is responsible for 20% of community-acquired sepsis cases and 40% of sepsis-related mortalities in northeast Thailand, and is intrinsically resistant to aminoglycosides, macrolides, rifamycins, cephalosporins, and nonureidopenicillins. There is no vaccine and its diagnosis is problematic. Biotin protein ligase (BirA) which is essential for fatty acid synthesis has been proposed as a drug target in bacteria. Very few bacterial BirA have been characterized, and a better understanding of these enzymes is necessary to further assess their value as drug targets. BirA within the Burkholderia genus have not yet been investigated. We present for the first time the cloning, expression, purification and functional characterisation of the putative Bp BirA and orthologous B. thailandensis (Bt) biotin carboxyl carrier protein (BCCP) substrate. A GFP-tagged Bp BirA was produced and applied for the development of a high-throughput (HT) assay based on our differential scanning fluorimetry of GFP-tagged proteins (DSF-GTP) principle as well as an electrophoretic mobility shift assay. Our biochemical data in combination with the new HT DSF-GTP and biotinylation activity assay could facilitate future drug screening efforts against this drug-resistant organism.
类鼻疽伯克霍尔德菌(Bp)是类鼻疽的病原体。该细菌导致了泰国东北部20%的社区获得性败血症病例以及40%与败血症相关的死亡,并且对氨基糖苷类、大环内酯类、利福霉素类、头孢菌素类和非脲基青霉素类药物具有内在抗性。目前尚无疫苗,其诊断也存在问题。脂肪酸合成所必需的生物素蛋白连接酶(BirA)已被提议作为细菌中的药物靶点。对细菌BirA的表征非常少,为了进一步评估它们作为药物靶点的价值,有必要更好地了解这些酶。伯克霍尔德菌属内的BirA尚未得到研究。我们首次展示了假定的Bp BirA和同源的泰国伯克霍尔德菌(Bt)生物素羧基载体蛋白(BCCP)底物的克隆、表达、纯化及功能表征。我们制备了一种绿色荧光蛋白(GFP)标记的Bp BirA,并基于我们的GFP标记蛋白差示扫描荧光法(DSF-GTP)原理以及电泳迁移率变动分析开发了一种高通量(HT)检测方法。我们的生化数据与新的HT DSF-GTP和生物素化活性检测相结合,有助于未来针对这种耐药生物体的药物筛选工作。